Programa de monitorización de la vigilancia activa en cáncer de próstata en España de la Sociedad Española de Urología; resultados preliminares

The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry

“…Recently, the initial results of the PASS study (clinicaltrials.gov NCT00756665) have been published, with a median follow-up of 28 months: 24% of their patients faced adverse reclassification [ 3 ]. These data are frequently found in a current database like ours [ 2 ] among others [ 12 , 13 ], all of which have been previously driven by the uncertainty of the common selection criteria used. Using a cohort of 859 Gleason 6 PCa patients, in their late study the same group has proposed an easy to use online prediction tool [ 14 ] of progression in AS, with widely used and reproducible covariates.…”

“…Active surveillance (AS) is increasingly being implemented by urologists as a strategy that provides the benefits from prostate cancer (PCa) opportunistic screening observed in western countries [ 1 ], but avoids overtreatment. We have presented our National Registry (AEU/PIEM/2014/0001, www.piem.aeu.es ) supported by the Spanish Urological Association (Asociación Española de Urología, AEU) [ 2 ]. This initiative was created with the aim of facilitating the implementation of AS in all types of Hospitals, and of providing an opportunity for multicentric clinical research, as different inclusion criteria and follow-up strategies are allowed.…”

“…As the PASS and AEU protocols are comparable in their design [ 2 , 3 ], we aim to perform an external validation of this PASS-RC with a different population. We understand that our external validation study specially focused on defining clinical utility of PASS-RC could make this tool a useful help for decision making in men on AS.…”